



## rilzabrutinib (PRN1008) | BTK

oral reversible covalent BTK inhibitor  
in Ph. III for immune thrombocytopenia  
from structure-based drug design + opt.  
*J. Med. Chem.*  
Principia Biopharma (Sanofi), So. San Francisco, CA




## INE963 | Pf 3D7

oral blood stage antimalarial  
in Ph. I (healthy volunteers)  
from 1.5M compd phenotypic screen + opt.  
*J. Med. Chem.*  
Novartis (NIBR), Emeryville, CA




## ulevostinag (MK-1454) | STING

intratumoral STING agonist  
in Ph. II for met. HNSCC  
cyclic dinucleotide derivative  
*J. Med. Chem.*  
Merck, Kenilworth, NJ




## compound 24 | KIF18A

oral kinesin motor protein inhibitor  
relative AMG 650 in Ph. I for cancer  
from ~600k compounds HTS + opt  
*J. Med. Chem.*  
Amgen, Thousand Oaks, CA




## compound 10 | PPAR $\gamma$

oral PPAR $\gamma$  phosphorylation inhibitor, partial  
agonist  
efficacy in diabetic mouse model  
from structure-based virtual screen  
*ACS Med. Chem. Lett.*  
AstraZeneca, Gothenburg, SE




## etavopivat | PKR

oral pyruvate kinase activator  
in Ph. II/III for genetic anemias  
200 or 400 mg QD, follows etavopivat  
*J Pharmacol Exp Ther.*  
Forma Therapeutics, Watertown, MA




## BMS-986176/LX-9211 | AAK1

oral CNS-penetrant AAK1 kinase inhibitor  
in Ph. II for neuropathic pain  
from high-throughput screen + opt.  
*J. Med. Chem.*  
Bristol-Myers Squibb, Wallingford, CT




## branaplam | SMN2

oral, CNS-penetrant splicing modulator  
w/ HTT activity  
in Ph. II for Huntington's (prev. SMA)  
further characterization of SMA candidate  
*Nat. Commun.*  
Novartis, Cambridge, MA



## MAK683 | PRC2 (EED subunit)

oral, allosteric PRC2 inhibitor (EED)  
in Ph. I/II for cancer (DLBCL); preliminary efficacy  
from micromolar HTS hit  
*J. Med. Chem.*  
Novartis, Emeryville, CA



## HR1405-01 | COX

intravenous NSAID  
faster  $T_{max}$  and lower dose vs. loxoprofen in Ph. I  
from loxoprofen metabolite  
*Eur. J. Med. Chem.*  
Nanjing Heron Pharmaceutical Co., Nanjing, CN